Anti-CD39 / ENTPD1, clone r22A9

0.2 mg/ml in 1X PBS with 0.05% BSA, 0.05% sodium azide. ENTPD1 Antibody recognizes CD39, also known as Ectonucleoside triphosphate diphosphohydrolase 1, a plasma membrane ectoenzyme that regulates extracellular nucleotide signaling. Encoded by the ENTPD1 gene, CD39 hydrolyzes extracellular ATP and ADP to AMP, thereby modulating purinergic signaling pathways involved in inflammation, thrombosis, and immune regulation. ENTPD1 Antibody is suitable for detecting CD39 expression in research applications focused on immune homeostasis and tumor microenvironment biology.ENTPD1 antibody, also referred to as CD39 antibody and NTPDase1 antibody in the literature, targets a glycosylated transmembrane protein expressed on endothelial cells, regulatory T cells, B cells, monocytes, macrophages, and selected epithelial populations. By limiting extracellular ATP and cooperating with CD73 to generate adenosine, CD39 contributes to immunosuppressive signaling pathways that regulate lymphocyte activation and maintain vascular homeostasis. Increased CD39 expression has been associated with immune tolerance and tumor-associated immune suppression.The ENTPD1 gene is located on chromosome 10q24.1 and encodes a protein containing two transmembrane regions and a large extracellular catalytic domain with conserved apyrase motifs required for nucleotide hydrolysis. CD39 localizes predominantly to the plasma membrane and demonstrates membranous staining in endothelial and immune cell populations in tissue sections. Expression is particularly prominent in lymphoid tissues such as tonsil and lymph node, as well as in vascular endothelium and placenta.Dysregulation of ENTPD1 expression has been implicated in cancer progression, chronic inflammatory disease, thrombosis, and cardiovascular disorders. Clone r22A9 is a recombinant mouse monoclonal antibody developed to recognize ENTPD1 / CD39 in experimental systems.